Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Strategies for Preparing Different Types of Lipid Polymer Hybrid Nanoparticles in Targeted Tumor Therapy

Author(s): Yong Zhuang, Yiye Zhao, Bingyue Wang, Qi Wang, Tiange Cai* and Yu Cai*

Volume 27, Issue 19, 2021

Published on: 20 November, 2020

Page: [2274 - 2288] Pages: 15

DOI: 10.2174/1381612826666201120155558

Price: $65

conference banner
Abstract

At present, cancer is one of the most common diseases in the world, causing a large number of deaths and seriously affecting people's health. The traditional treatment of cancer is mainly surgery, radiotherapy or chemotherapy. Conventional chemotherapy is still an important treatment, but it has some shortcomings, such as poor cell selectivity, serious side effects, drug resistance and so on. Nanoparticle administration can improve drug stability, reduce toxicity, prolong drug release time, prolong system half-life, and bring broad prospects for tumor therapy. Lipid polymer hybrid nanoparticles (LPNs), which combine the advantages of polymer core and phospholipid shell to form a single platform, have become multi-functional drug delivery platforms. This review introduces the basic characteristics, structure and preparation methods of LPNs, and discusses targeting strategies of LPNs in tumor therapy in order to overcome the defects of traditional drug therapy.

Keywords: Lipid polymer hybrid nanoparticles, preparation method, tumor, active targeting, physical and chemical targeting, chemotherapy.

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018; 68(6): 394-424.
[2]
Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013; 48(3): 416-27.
[http://dx.doi.org/10.1016/j.ejps.2012.12.006]
[3]
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discovery 2005; 4(2): 145-60.
[http://dx.doi.org/10.1038/nrd1632]
[4]
Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine 2015; 10: 1001-18.
[PMID: 25678788]
[5]
Wakaskar RR. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target 2018; 26(4): 311-8.
[http://dx.doi.org/10.1080/1061186X.2017.1367006] [PMID: 28797169]
[6]
Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine 2019; 14: 1937-52.
[http://dx.doi.org/10.2147/IJN.S198353] [PMID: 30936695]
[7]
Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. European J Pharm Biopharm 2013; 85(3): 427-43.
[http://dx.doi.org/10.1016/j.ejpb.2013.07.002]
[8]
Krishnamurthy S, Vaiyapuri R, Zhang L, et al. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomaterials Science 2015; 3(7): 923-36.
[http://dx.doi.org/10.1039/C4BM00427B]
[9]
Date T, Nimbalkar V, Kamat J, et al. Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. J Contr Rel 2018; 271: 60-73.
[http://dx.doi.org/10.1016/j.jconrel.2017.12.016]
[10]
Yalcin S. Dextran coated iron oxide nanoparticle for delivery of miR-29a to breast cancer cell line. Pharmac Develop Technol 2019; pp. 1-12.
[http://dx.doi.org/10.1080/10837450.2019.1623252]
[11]
Joshy KS, George A, Snigdha S, et al. Novel core-shell dextran hybrid nanosystem for anti-viral drug delivery. Mater Sci Eng C 2018; 93: 864-72.
[http://dx.doi.org/10.1016/j.msec.2018.08.015] [PMID: 30274122]
[12]
Huang S, Huang G. Preparation and drug delivery of dextran-drug complex. Drug Deliv 2019; 26(1): 252-61.
[http://dx.doi.org/10.1080/10717544.2019.1580322] [PMID: 30857442]
[13]
Tezgel Ö, Szarpak-Jankowska A, Arnould A, Auzély-Velty R, Texier I. Chitosan-lipid nanoparticles (CS-LNPs): Application to siRNA delivery. J Colloid Interface Sci 2018; 510: 45-56.
[http://dx.doi.org/10.1016/j.jcis.2017.09.045] [PMID: 28934610]
[14]
Fan Y, Zheng J, Liu J, et al. A Novel Baicalin-Loaded Polyelectrolyte Nanoparticle Formulation. 2016 8th International Conference on Information Technology in Medicine and Education (ITME) 2016; 23-5.
[15]
Liang X, Li X, Chang J, Duan Y, Li Z. Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer-targeted gene delivery. Langmuir 2013; 29(27): 8683-93.
[http://dx.doi.org/10.1021/la401166v] [PMID: 23763489]
[16]
Xie M, Zhang F, Liu L, et al. Surface modification of graphene oxide nanosheets by protamine sulfate/sodium alginate for anti-cancer drug delivery application. Appl Surf Sci 2018; 440: 853-60.
[http://dx.doi.org/10.1016/j.apsusc.2018.01.175]
[17]
Fan Y, Sahdev P, Ochyl LJ, et al. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens. J Contr Rel 2015; 208: 121-9.
[http://dx.doi.org/10.1016/j.jconrel.2015.04.010]
[18]
Tokarczyk K, Jachimska B. Characterization of G4 PAMAM dendrimer complexes with 5-fluorouracil and their interactions with bovine serum albumin. Colloids Surf A Physicochem Eng Asp 2019; 561: 357-63.
[http://dx.doi.org/10.1016/j.colsurfa.2018.10.080]
[19]
Fang DL, Chen Y, Xu B, et al. Development of lipid-shell and polymer core nanoparticles with water-soluble salidroside for anti-cancer therapy. Int J Mol Sci 2014; 15(3): 3373-88.
[http://dx.doi.org/10.3390/ijms15033373] [PMID: 24573250]
[20]
Hu Y, Hoerle R, Ehrich M, Zhang C. Engineering the lipid layer of lipid-PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability. Acta Biomater 2015; 28: 149-59.
[http://dx.doi.org/10.1016/j.actbio.2015.09.032] [PMID: 26428192]
[21]
Mandal B, Mittal NK, Balabathula P, et al. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. Eur J Pharma Sci 2016; 81: 162-71.
[http://dx.doi.org/10.1016/j.ejps.2015.10.021]
[22]
Zhang L, Wu S, Qin Y, et al. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy. Nano Let 2019; 19(7): 4237-49.
[23]
Aryal S, Hu CM, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm 2011; 8(4): 1401-7.
[http://dx.doi.org/10.1021/mp200243k] [PMID: 21696189]
[24]
Pukale SS, Sharma S, Dalela M, et al. Multi-component clobetasol-loaded monolithic lipid-polymer hybrid nanoparticles ameliorate imiquimod-induced psoriasis-like skin inflammation in Swiss albino mice. Acta Biomater 2020; 115: 393-409.
[http://dx.doi.org/10.1016/j.actbio.2020.08.020] [PMID: 32846238]
[25]
Gao L-Y, Liu X-Y, Chen C-J, et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials 2014; 35(6): 2066-78.
[http://dx.doi.org/10.1016/j.biomaterials.2013.11.046] [PMID: 24315577]
[26]
Fan W, Bu W, Shen B, et al. Intelligent MnO2 nanosheets anchored with upconversion nanoprobes for concurrent pH-/H2O2-responsive UCL imaging and oxygen-elevated synergetic therapy. Adv Mater 2015; 27(28): 4155-61.
[27]
Su X, Fricke J, Kavanagh DG, Irvine DJ. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm 2011; 8(3): 774-87.
[http://dx.doi.org/10.1021/mp100390w] [PMID: 21417235]
[28]
Mo R, Sun Q, Xue J, et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. (Deerfield Beach, Fla) 2012; 24(27): 3659-65.
[http://dx.doi.org/10.1002/adma.201201498]
[29]
Paxton WF, McAninch PT, Shin SHR, Brumbach MT. Adsorption and fusion of hybrid lipid/polymer vesicles onto 2D and 3D surfaces. Soft Matter 2018; 14(40): 8112-8.
[http://dx.doi.org/10.1039/C8SM00343B] [PMID: 30206612]
[30]
Liu Y, Pan J, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm 2010; 395(1-2): 243-50.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.008] [PMID: 20472049]
[31]
Lu T, Wang Z, Ma Y, Zhang Y, Chen T. Influence of polymer size, liposomal composition, surface charge, and temperature on the permeability of pH-sensitive liposomes containing lipid-anchored poly(2-ethylacrylic acid). Int J Nanomedicine 2012; 7: 4917-26.
[http://dx.doi.org/10.2147/IJN.S35576] [PMID: 23028220]
[32]
Paolino D, Accolla ML, Cilurzo F, et al. Interaction between PEG lipid and DSPE/DSPC phospholipids: An insight of PEGylation degree and kinetics of de-PEGylation. Colloids Surf B Biointerfaces 2017; 155: 266-75.
[http://dx.doi.org/10.1016/j.colsurfb.2017.04.018] [PMID: 28460301]
[33]
Thao LQ, Lee C, Kim B, et al. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids Surf B Biointerfaces 2017; 152: 183-91.
[http://dx.doi.org/10.1016/j.colsurfb.2017.01.017] [PMID: 28110040]
[34]
Yu Y, Zhang X, Qiu L. The anti-tumor efficacy of curcumin when delivered by size/charge-changing multistage polymeric micelles based on amphiphilic poly(β-amino ester) derivates. Biomaterials 2014; 35(10): 3467-79.
[http://dx.doi.org/10.1016/j.biomaterials.2013.12.096] [PMID: 24439418]
[35]
Ruttala HB, Ko YT. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids Surf B Biointerfaces 2015; 128: 419-26.
[http://dx.doi.org/10.1016/j.colsurfb.2015.02.040] [PMID: 25797481]
[36]
Tran TH, Ramasamy T, Choi JY, et al. Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells. Int J Nanomedicine 2015; 10: 5249-62.
[PMID: 26346426]
[37]
Shi J, Xiao Z, Votruba AR, Vilos C, Farokhzad OC. Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew Chem Int Ed Engl 2011; 50(31): 7027-31.
[http://dx.doi.org/10.1002/anie.201101554] [PMID: 21698724]
[38]
Bose RJ, Arai Y, Ahn JC, Park H, Lee SH. Influence of cationic lipid concentration on properties of lipid-polymer hybrid nanospheres for gene delivery. Int J Nanomedicine 2015; 10: 5367-82.
[PMID: 26379434]
[39]
Li J, He YZ, Li W, Shen YZ, Li YR, Wang YF. A novel polymer-lipid hybrid nanoparticle for efficient nonviral gene delivery. Acta Pharmacol Sin 2010; 31(4): 509-14.
[http://dx.doi.org/10.1038/aps.2010.15] [PMID: 20348944]
[40]
Xue HY, Tran N, Wong HL. A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy. Eur J Pharm Biopharm 2016; 108: 68-75.
[http://dx.doi.org/10.1016/j.ejpb.2016.08.014] [PMID: 27569032]
[41]
Dave V, Tak K, Sohgaura A, et al. Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications. J Microbiol Methods 2019; 160: 130-42.
[42]
Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine: Nanotechnology. Biol Med 2013; 9(4): 474-91.
[http://dx.doi.org/10.1016/j.nano.2012.11.010]
[43]
Zhang RX, Ahmed T. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks 2017; 9(4): 1334-55.
[http://dx.doi.org/10.1039/C6NR08486A]
[44]
Shuhendler AJ, Prasad P, Zhang RX, et al. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm 2014; 11(8): 2659-74.
[http://dx.doi.org/10.1021/mp500093c] [PMID: 24830351]
[45]
Rao S, Prestidge CA. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv 2016; 13(5): 691-707.
[http://dx.doi.org/10.1517/17425247.2016.1151872] [PMID: 26866382]
[46]
Zhao X, Li F, Li Y, et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials 2015; 46: 13-25.
[http://dx.doi.org/10.1016/j.biomaterials.2014.12.028] [PMID: 25678112]
[47]
Wang AZ, Yuet K, Zhang L, et al. ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (Lond) 2010; 5(3): 361-8.
[http://dx.doi.org/10.2217/nnm.10.6] [PMID: 20394530]
[48]
Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs. Nanomaterials (Basel) 2017; 7(6): 122.
[http://dx.doi.org/10.3390/nano7060122] [PMID: 28554993]
[49]
Salvador-Morales C, Brahmbhatt B, Márquez-Miranda V, et al. Mechanistic studies on the self-assembly of PLGA patchy particles and their potential applications in biomedical imaging. Langmuir 2016; 32(31): 7929-42.
[http://dx.doi.org/10.1021/acs.langmuir.6b02177] [PMID: 27468612]
[50]
Carmona-Ribeiro AM. Biomimetic lipid polymer nanoparticles for drug delivery Nanoparticles in Biology and Medicine: Methods and Protocols. New York, NY. Springer, US 2020; pp. 45-60.
[http://dx.doi.org/10.1007/978-1-0716-0319-2_4]
[51]
Bose RJ, Lee SH, Park H. Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments. Drug Discov Today 2016; 21(8): 1303-12.
[http://dx.doi.org/10.1016/j.drudis.2016.06.005] [PMID: 27297732]
[52]
Narain A, Asawa S, Chhabria V, Patil-Sen Y. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine (Lond) 2017; 12(21): 2677-92.
[http://dx.doi.org/10.2217/nnm-2017-0225] [PMID: 28965474]
[53]
Hu C-MJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011; 108(27): 10980-5.
[http://dx.doi.org/10.1073/pnas.1106634108] [PMID: 21690347]
[54]
Hu C-MJ, Fang RH, Wang K-C, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015; 526(7571): 118-21.
[http://dx.doi.org/10.1038/nature15373] [PMID: 26374997]
[55]
Aoki I, Yoneyama M, Hirose J, et al. Thermoactivatable polymer-grafted liposomes for low-invasive image-guided chemotherapy. Translational Research 2015; 166(6): 660-73.
[http://dx.doi.org/10.1016/j.trsl.2015.07.009]
[56]
Lee S-M, Ahn RW, Chen F, et al. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano 2010; 4(9): 4971-8.
[http://dx.doi.org/10.1021/nn100560p]
[57]
Kokuryo D, Nakashima S, Ozaki F, et al. Evaluation of thermo-triggered drug release in intramuscular-transplanted tumors using thermosensitive polymer-modified liposomes and MRI. Nanomedicine (Lond) 2015; 11(1): 229-38.
[http://dx.doi.org/10.1016/j.nano.2014.09.001] [PMID: 25229542]
[58]
Mieszawska AJ, Gianella A, Cormode DP, et al. Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chemical communications (Cambridge, England) 2012; 48(47): 5835-7.
[http://dx.doi.org/10.1039/c2cc32149a]
[59]
Thevenot J, Troutier AL, David L, Delair T, Ladavière C. Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules 2007; 8(11): 3651-60.
[http://dx.doi.org/10.1021/bm700753q] [PMID: 17958441]
[60]
Zhao P, Wang H, Yu M, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2012; 81(2): 248-56.
[61]
Yalcin TE, Ilbasmis-Tamer S, Takka S. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo. Int J Pharm 2020; 580: 119246.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119246] [PMID: 32205141]
[62]
Thanki K, Zeng X, Foged C. Preparation, characterization, and in vitro evaluation of lipidoid-polymer hybrid nanoparticles for siRNA delivery to the cytosol. Methods Mol Biol 2019; 1943: 141-52.
[http://dx.doi.org/10.1007/978-1-4939-9092-4_9] [PMID: 30838614]
[63]
Palange AL, Di Mascolo D, Carallo C, Gnasso A, Decuzzi P. Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine (Lond) 2014; 10(5): 991-1002.
[http://dx.doi.org/10.1016/j.nano.2014.02.004] [PMID: 24566270]
[64]
Zhang T, Ma J, Li C, et al. Core-shell lipid polymer nanoparticles for combined chemo and gene therapy of childhood head and neck cancers. Oncol Rep 2017; 37(3): 1653-61.
[http://dx.doi.org/10.3892/or.2017.5365] [PMID: 28098869]
[65]
Liu J, Cheng H, Han L, et al. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 2018; 12: 3199-209.
[http://dx.doi.org/10.2147/DDDT.S172199] [PMID: 30288024]
[66]
Gu L, Shi T, Sun Y, et al. Folate-modified, indocyanine green-loaded lipid-polymer hybrid nanoparticles for targeted delivery of cisplatin. J Biomater Sci Polym Ed 2017; 28(7): 690-702.
[http://dx.doi.org/10.1080/09205063.2017.1296347] [PMID: 28277002]
[67]
Seedat N, Kalhapure RS, Mocktar C, et al. Co-encapsulation of multi-lipids and polymers enhances the performance of vancomycin in lipid-polymer hybrid nanoparticles: In vitro and in silico studies. Mater Sci Eng C 2016; 61: 616-30.
[http://dx.doi.org/10.1016/j.msec.2015.12.053] [PMID: 26838890]
[68]
Zhang L, Zhu D, Dong X, et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine 2015; 10: 2101-14.
[PMID: 25844039]
[69]
Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008; 2(8): 1696-702.
[70]
Dong W, Wang X, Liu C, et al. Chitosan based polymer-lipid hybrid nanoparticles for oral delivery of enoxaparin. Int J Pharm 2018; 547(1): 499-505.
[http://dx.doi.org/10.1016/j.ijpharm.2018.05.076]
[71]
Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces 2011; 85(2): 214-20.
[http://dx.doi.org/10.1016/j.colsurfb.2011.02.033] [PMID: 21439797]
[72]
Troutier AL, Delair T, Pichot C, Ladavière C. Physicochemical and interfacial investigation of lipid/polymer particle assemblies. Langmuir 2005; 21(4): 1305-13.
[http://dx.doi.org/10.1021/la047659t] [PMID: 15697275]
[73]
Stolzoff M, Ekladious I, Colby AH, Colson YL, Porter TM, Grinstaff MW. Synthesis and characterization of hybrid polymer/lipid expansile nanoparticles: imparting surface functionality for targeting and stability. Biomacromolecules 2015; 16(7): 1958-66.
[http://dx.doi.org/10.1021/acs.biomac.5b00336] [PMID: 26053219]
[74]
Wang Q, Alshaker H, Böhler T, et al. Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. Sci Rep 2017; 7(1): 5901.
[http://dx.doi.org/10.1038/s41598-017-06142-x]
[75]
Devrim B, Kara A, Vural İ, Bozkır A. Lysozyme-loaded lipid-polymer hybrid nanoparticles: preparation, characterization and colloidal stability evaluation. Drug Dev Ind Pharm 2016; 42(11): 1865-76.
[http://dx.doi.org/10.1080/03639045.2016.1180392] [PMID: 27091346]
[76]
Agrawal U, Chashoo G, Sharma PR, Kumar A, Saxena AK, Vyas SP. Tailored polymer-lipid hybrid nanoparticles for the delivery of drug conjugate: dual strategy for brain targeting. Colloids Surf B Biointerfaces 2015; 126: 414-25.
[http://dx.doi.org/10.1016/j.colsurfb.2014.12.045] [PMID: 25601092]
[77]
Zhang RX, Cai P, Zhang T, et al. Polymer–lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine: Nanotechnology. Biol Med 2016; 12(5): 1279-90.
[http://dx.doi.org/10.1016/j.nano.2015.12.383]
[78]
Chitkara D, Singh S, Mittal A. Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. Ther Deliv 2016; 7(4): 245-55.
[http://dx.doi.org/10.4155/tde-2015-0003] [PMID: 27010986]
[79]
Aryal S, Key J, Stigliano C, Ananta JS, Zhong M, Decuzzi P. Engineered magnetic hybrid nanoparticles with enhanced relaxivity for tumor imaging. Biomaterials 2013; 34(31): 7725-32.
[http://dx.doi.org/10.1016/j.biomaterials.2013.07.003] [PMID: 23871540]
[80]
Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63(3): 136-51.
[http://dx.doi.org/10.1016/j.addr.2010.04.009] [PMID: 20441782]
[81]
Maeda H. Polymer therapeutics and the EPR effect. J Drug Target 2017; 25(9-10): 781-5.
[http://dx.doi.org/10.1080/1061186X.2017.1365878] [PMID: 28988499]
[82]
Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012; 14: 1-16.
[http://dx.doi.org/10.1146/annurev-bioeng-071811-150124] [PMID: 22524388]
[83]
Du M, Ouyang Y, Meng F, et al. Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer. Int J Pharm 2019; 561: 274-82.
[http://dx.doi.org/10.1016/j.ijpharm.2019.03.006]
[84]
Yugui F, Wang H, Sun D, et al. Nasopharyngeal cancer combination chemoradiation therapy based on folic acid modified, gefitinib and yttrium 90 co-loaded, core-shell structured lipid-polymer hybrid nanoparticles. Biomedicine Pharmacother 2019; 114: 108820.
[http://dx.doi.org/10.1016/j.biopha.2019.108820]
[85]
Zheng M, Gong P, Zheng C, et al. Lipid-polymer nanoparticles for folate-receptor targeting delivery of doxorubicin. J Nanosci Nanotechnol 2015; 15(7): 4792-8.
[http://dx.doi.org/10.1166/jnn.2015.9604] [PMID: 26373039]
[86]
Li ZH, Zhou Y, Ding YX, Guo QL, Zhao L. Roles of integrin in tumor development and the target inhibitors. Chin J Nat Med 2019; 17(4): 241-51.
[http://dx.doi.org/10.1016/S1875-5364(19)30028-7] [PMID: 31076128]
[87]
Li Y, Xiao Y, Lin HP, et al. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials 2019; 188: 160-72.
[http://dx.doi.org/10.1016/j.biomaterials.2018.10.019] [PMID: 30352320]
[88]
Gao F, Zhang J, Fu C, et al. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability. Int J Nanomedicine 2017; 12: 4147-62.
[http://dx.doi.org/10.2147/IJN.S134148] [PMID: 28615942]
[89]
Wang G, Wang Z, Li C, et al. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother 2018; 106: 275-84.
[http://dx.doi.org/10.1016/j.biopha.2018.06.137]
[90]
Cui Y, Xu Q, Chow PK-H, Wang D, Wang CH. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013; 34(33): 8511-20.
[http://dx.doi.org/10.1016/j.biomaterials.2013.07.075] [PMID: 23932498]
[91]
Yu Z, Chen F, Qi X, et al. Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells. Exp Ther Med 2018; 15(2): 1247-56.
[PMID: 29399118]
[92]
Chen Y, Deng Y, Zhu C, et al. Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles. Biomed Pharmacother 2020; 127: 110181.
[93]
Li J, Xu W, Yuan X, et al. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. Int J Nanomedicine 2017; 12: 6909-21.
[http://dx.doi.org/10.2147/IJN.S144184] [PMID: 29075110]
[94]
Gao J, Xia Y, Chen H, et al. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond) 2014; 9(2): 279-93.
[http://dx.doi.org/10.2217/nnm.13.20] [PMID: 23721168]
[95]
Hu CM, Kaushal S, Tran Cao HS, et al. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm 2010; 7(3): 914-20.
[http://dx.doi.org/10.1021/mp900316a] [PMID: 20394436]
[96]
Clawson C, Ton L, Aryal S, Fu V, Esener S, Zhang L. Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding. Langmuir 2011; 27(17): 10556-61.
[http://dx.doi.org/10.1021/la202123e] [PMID: 21806013]
[97]
Wu B, Lu S-T, Deng K, et al. MRI-guided targeting delivery of doxorubicin with reduction-responsive lipid-polymer hybrid nanoparticles. Int J Nanomedicine 2017; 12: 6871-82.
[http://dx.doi.org/10.2147/IJN.S143048] [PMID: 29066883]
[98]
Luo Y, Yin X, Yin X, et al. Dual pH/redox-responsive mixed polymeric micelles for anticancer drug delivery and controlled release. Pharmaceutics 2019; 11(4): 176.
[http://dx.doi.org/10.3390/pharmaceutics11040176] [PMID: 30978912]
[99]
Kong SD, Sartor M, Hu C-MJ, Zhang W, Zhang L, Jin S. Magnetic field activated lipid-polymer hybrid nanoparticles for stimuli-responsive drug release. Acta Biomater 2013; 9(3): 5447-52.
[http://dx.doi.org/10.1016/j.actbio.2012.11.006] [PMID: 23149252]
[100]
Jain S, Valvi PU, Swarnakar NK, Thanki K. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol Pharm 2012; 9(9): 2542-53.
[http://dx.doi.org/10.1021/mp300320d] [PMID: 22845020]
[101]
Ramasamy T, Tran TH, Cho HJ, et al. Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharmaceutical Research 2014; 31(5): 1302-14.
[102]
Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006; 23(7): 1574-85.
[http://dx.doi.org/10.1007/s11095-006-0282-x] [PMID: 16786442]
[103]
Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007; 65(3): 300-8.
[http://dx.doi.org/10.1016/j.ejpb.2006.10.022] [PMID: 17156986]
[104]
Ramasamy T, Tran TH, Choi JY, et al. Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr Polym 2014; 102: 653-61.
[http://dx.doi.org/10.1016/j.carbpol.2013.11.009] [PMID: 24507332]
[105]
Colombo S, Cun D, Remaut K, et al. Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles. J Control Release 2015; 201: 22-31.
[http://dx.doi.org/10.1016/j.jconrel.2014.12.026] [PMID: 25540904]
[106]
Wu XY. Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery. Taylor & Francis 2016.
[http://dx.doi.org/10.1517/17425247.2016.1165662]
[107]
Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008; 2(8): 1696-702.
[http://dx.doi.org/10.1021/nn800275r] [PMID: 19206374]
[108]
Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release 2008; 128(1): 60-70.
[http://dx.doi.org/10.1016/j.jconrel.2008.02.014] [PMID: 18406489]
[109]
Chavanpatil MD, Khdair A, Panyam J. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules. Pharm Res 2007; 24(4): 803-10.
[http://dx.doi.org/10.1007/s11095-006-9203-2] [PMID: 17318416]
[110]
Du M, Ouyang Y, Meng F, et al. Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer. Int J Pharm 2019; 561: 274-82.
[http://dx.doi.org/10.1016/j.ijpharm.2019.03.006] [PMID: 30851393]
[111]
Li Y, Wu H, Yang X, et al. Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. Mol Pharm 2014; 11(8): 2915-27.
[http://dx.doi.org/10.1021/mp500254j] [PMID: 24984984]
[112]
Crayton SH, Tsourkas A. pH-titratable superparamagnetic iron oxide for improved nanoparticle accumulation in acidic tumor microenvironments. ACS Nano 2011; 5(12): 9592-601.
[http://dx.doi.org/10.1021/nn202863x] [PMID: 22035454]
[113]
Dreaden EC, Morton SW, Shopsowitz KE, et al. Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles. ACS Nano 2014; 8(8): 8374-82.
[http://dx.doi.org/10.1021/nn502861t] [PMID: 25100313]
[114]
Koren E, Apte A, Jani A, et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Contr Rel Society 2012; 160(2): 264-73.
[115]
Li L, Sun W, Zhong J, et al. Multistage nanovehicle delivery system based on stepwise size reduction and charge reversal for programmed nuclear targeting of systemically administered anticancer drugs. Adv Funct Mater 2015; 25(26): 4101-13.
[http://dx.doi.org/10.1002/adfm.201501248]
[116]
Chen B, Dai W, He B, et al. Current multistage drug delivery systems based on the tumor microenvironment. Theranostics 2017; 7(3): 538-58.
[http://dx.doi.org/10.7150/thno.16684] [PMID: 28255348]
[117]
Chen H, Moore T, Qi B, et al. Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence. ACS Nano 2013; 7(2): 1178-87.
[http://dx.doi.org/10.1021/nn304369m] [PMID: 23281651]
[118]
Yan L, Crayton SH, Thawani JP, et al. A pH-responsive drug-delivery platform based on glycol chitosan-coated liposomes. Small (Weinheim an der Bergstrasse, Germany) 2015; 11(37): 4870.
[http://dx.doi.org/10.1002/smll.201501412]
[119]
Sun Q, Sun X, Ma X, et al. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs. Adv Mater (Deerfield Beach, Fla) 2014; 26(45): 7615-21.
[http://dx.doi.org/10.1002/adma.201401554]
[120]
Zhao Z, Meng H, Wang N, et al. A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery. Angew Chem Int Ed Engl 2013; 52(29): 7487-91.
[http://dx.doi.org/10.1002/anie.201302557] [PMID: 23757374]
[121]
Ke CJ, Chiang WL, Liao ZX, et al. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials 2013; 34(1): 1-10.
[http://dx.doi.org/10.1016/j.biomaterials.2012.09.023] [PMID: 23044041]

Rights & Permissions Print Cite
Article Metrics
48
1
Wayfinder Image
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy